MapLight Therapeutics

Company snapshot

Moonlight Therapeutics is focused on developing safe, effective, and patient-friendly treatments for people suffering from food allergies. Our first treatment is for children and adults with peanut allergies.

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MapLight Therapeutics. Not investment advice.

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for MapLight Therapeutics.

1. Jun 8, 2026 Clinical update

   ML-004 (IR)/(ER) tablet — Phase 2

2. Jun 5, 2026 Clinical update

   Placebo for ML-007C-MA bilayer tablet — Phase 2

3. Jun 5, 2026 Clinical update

   Placebo — Phase 2

4. Jun 5, 2026 Clinical update

   ML-007C-MA — Phase 2

5. May 23, 2026 Clinical update

   ML-007C-MA — Phase 2

View all clinical trial activity →

• What is MapLight Therapeutics?

  MapLight Therapeutics is a pharma organization headquartered in atlanta, USA. It trades on NYSE under ticker MPLT. Primary therapeutic focus areas include Schizophrenia, Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis, Autism Spectrum Disorder, Psychosi

• Is MapLight Therapeutics publicly traded?

  Yes. MapLight Therapeutics is listed with ticker MPLT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does MapLight Therapeutics develop or market?

  We link 5 drug profile(s) where MapLight Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/maplight-therapeutics#company-drugs.

• What are the latest developments for MapLight Therapeutics?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does MapLight Therapeutics focus on?

  MapLight Therapeutics focuses on Schizophrenia, Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis, Autism Spectrum Disorder based on our analysis of their pipeline programs and drug development activities.